Paracip

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Paracip

Quick Facts

Property Description
Active Ingredient Acetaminophen (Paracetamol)
Pharmacological Class Analgesic, Antipyretic (Non-Opioid)
Primary Form Tablet (Oral)
Origin Synthetic Compound
Common Use Relief of pain and fever

What is Paracip?

Paracip is a commercially recognized pharmaceutical preparation, a trade name whose active ingredient is Acetaminophen, globally known by the generic name Paracetamol. This medicine is functionally categorized as an analgesic (pain reliever) and antipyretic (fever reducer), placing it within the broader group of Non-Opioid Analgesics. This classification dictates its core therapeutic purpose: to provide effective, symptomatic relief from mild to moderate pain and to aid in the reduction of elevated body temperature.

Identity, Chemical Composition, and Origin

Paracip is a commercial single-ingredient product containing the synthetic compound Acetaminophen, a substance chemically derived as a Para-aminophenol derivative. This origin signifies that the core active ingredient is produced entirely through laboratory synthesis, rather than being extracted from a natural source. While the active ingredient, Acetaminophen, is utilized in numerous global formulations, Paracip is typically positioned as an Over-the-Counter (OTC) option designed for accessible symptomatic relief. Pharmacological studies widely support the bioequivalence of various Paracetamol preparations, confirming the reliability of its therapeutic effect across different trade formulations.

Pharmacological Class and Essential Function

The classification of Paracip is clinically recognized for its dual actions: increasing the pain threshold and regulating the body's thermoregulatory center. The World Health Organization includes this substance on its Model List of Essential Medicines, affirming its established safety and efficacy for core symptomatic relief. This function makes it suitable for common, neutral use scenarios, such as managing a temporary fever or easing general body aches. The most common presentation of Paracip is the solid tablet form, designed for simple oral use, facilitating its role as a foundational, dual-purpose medicine.

Regulatory References

  1. MedlinePlus Acetaminophen Entry
  2. WHO Essential Medicines List Entry for Paracetamol

What side effects are possible with Paracip?

Possible Side Effects and Safety Information

Paracip, containing paracetamol (acetaminophen), is generally well-tolerated at recommended doses, but it carries essential safety warnings documented by regulatory authorities (e.g., FDA, EMA) primarily concerning hepatotoxicity and severe hypersensitivity reactions.


Documented Adverse Reactions

The most commonly reported adverse effects are typically mild and transient, primarily affecting the gastrointestinal system, and may include nausea, vomiting, diarrhea, abdominal pain, or indigestion. The frequency of these events is generally low.

Adverse Reaction Category Examples of Specific Reactions
Serious Hepatic Acute liver failure (potentially fatal), increased liver enzymes.
Serious Dermatologic Severe skin reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis).
Hematologic (Rare) Thrombocytopenia (low platelet count), agranulocytosis.

Critical Safety Considerations

Hepatotoxicity Risk: The most critical safety concern is the risk of severe liver damage or failure. This risk is dose-dependent and significantly elevated if the maximum daily dose is exceeded, the drug is used for prolonged periods, or if the user consumes three or more alcoholic drinks daily while using the product. Regulatory bodies advise seeking emergency medical attention immediately if an overdose is suspected, even without immediate symptoms.

Serious Skin Reactions: Acetaminophen is associated with rare, but potentially fatal, skin reactions. Patients who develop a rash, peeling, or blistering of the skin must stop taking the medicine immediately and seek professional medical care.

Population Cautions: Use with caution is advised for patients with pre-existing severe liver impairment or those who are chronically malnourished.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Paracip (Acetaminophen) overdose establishes the critical risk of Severe Liver Damage (Hepatotoxicity), which is documented to progress to Acute Liver Failure (ALF) and can lead to death. Initial manifestations documented in regulatory sources commonly include non-specific symptoms such as nausea, vomiting, sweating, paleness, and abdominal pain in the upper right quadrant. Signs of advanced toxicity include jaundice, dark urine, and confusion. Life-threatening hypersensitivity reactions like bronchospasm are also documented complications.

When to Seek Urgent Help: Official Mandate

Regulatory documents explicitly mandate that individuals seek immediate medical attention for any suspected overdose event, regardless of whether initial symptoms are currently present. Contacting emergency services or poison control is required. This immediate action is critical because the specific antidote, N-acetylcysteine (NAC), is documented to offer maximal protective effect against hepatic injury when administered within the optimal time window.

Overdose management requires continuous medical monitoring. This involves obtaining serum acetaminophen concentration measurements and closely observing hepatic and renal function tests (e.g., AST/ALT, Creatinine). Official labeling notes an increased risk of toxicity for specific patient populations, including those with pre-existing hepatic impairment or chronic alcoholism.

Therapeutic Uses of Paracip

The active ingredient in Paracip is commonly used to help with symptoms related to physical discomfort and systemic imbalance for conditions presenting with mild to moderate pain. This application is widely recognized for short-term symptomatic assistance.

Symptomatic Relief for Pain and Systemic Imbalance

This medication is commonly used to help with easing symptoms related to discomfort associated with various acute or disruptive episodes, which may include symptoms of increased neurological or muscular activity. The medication is commonly used to help with symptom clusters that interfere with daily functioning, such as elevated body temperature (fever) and generalized body aches characteristic of cold and flu symptoms. This supportive benefit contributes to easing the overall symptom load for patients, and supports general well-being during symptomatic phases, making it relevant for managing symptoms across a broad range of patient groups.

Quick Fact: Relief for Pain Quick Fact: Relief for Fever
Helps address symptoms related to physical discomfort. Helps address symptoms related to systemic imbalance.
May assist with easing headaches, muscle aches, and toothache. Contributes to improved comfort during phases of high temperature.

Regulatory References

  1. NIH's StatPearls overview

Eligibility and Restrictions for Use

The eligibility profile for Paracip (Acetaminophen/Paracetamol) defines specific populations for whom use is prohibited, restricted, or permitted under defined conditions, based on regulatory labeling.


Absolute Contraindications (Must Not Use)

  • Hypersensitivity: Patients with a known allergy to Paracip/Acetaminophen or any of its inactive ingredients.
  • Severe Hepatic Impairment: Patients with severe active liver disease or severe hepatocellular insufficiency.

Eligibility-Related Restrictions

  • Hepatic/Renal Impairment: Use requires caution in patients with moderate hepatic insufficiency (including Gilbert's Syndrome) or severe renal impairment. Regulatory documents mandate that these groups may require a restricted total daily dose or a prolonged dosing interval.
  • Comorbidities: Use is restricted and requires caution in cases of chronic alcoholism, chronic malnutrition, dehydration, or G6PD deficiency. The maximum daily dose for adults weighing less than 50 kg is also limited.

Age and Physiological Eligibility Status

  • Adults and Older Adults are generally permitted to use the medicine under standard conditions, with no specific dose adjustment required solely for age.
  • Pediatric use is dependent on the specific formulation; certain tablets are not recommended for children under specific ages (e.g., 10 years), and some product forms may have effectiveness not established for children younger than two years.
  • Pregnancy and Lactation: Use is generally permitted if clinically needed, provided the lowest effective dose is used for the shortest possible duration.

What should I know about interactions with other medicines?

Paracip (Acetaminophen/Paracetamol) has documented interaction patterns that are formally classified in regulatory documents, focusing primarily on metabolism, absorption, and pharmacodynamic effects. Co-administration with any other product containing acetaminophen is strictly prohibited due to the officially documented risk of liver damage and overdose.

Pharmacokinetic and Metabolic Interactions

Interacting Substance/Class Regulatory Outcome Classification
Liver enzyme-inducing agents (e.g., Phenytoin, Rifampicin, Carbamazepine) Increased risk of hepatotoxicity through enhanced formation of toxic metabolites. Pharmacokinetic
Probenecid Significantly reduces clearance by inhibiting conjugation with glucuronic acid. Clearance Modification
Metoclopramide, Domperidone Increase the speed of absorption of Paracip. Absorption Rate
Cholestyramine Reduces the absorption; administration must be separated by several hours (e.g., 1 hour before or 4 hours after). Timing-Based Restriction

Pharmacodynamic and Substance Interactions

Warfarin and other coumarins may have their anticoagulant effect enhanced by the regular, prolonged use of Paracip, which increases the documented risk of bleeding. This is categorized as a pharmacodynamic interaction. Regular heavy consumption of alcohol is officially associated with an increased hazard of severe liver damage when Paracip is used. Furthermore, concurrent use with Flucloxacillin is noted for an association with the risk of high anion gap metabolic acidosis, which is exacerbated in patients with certain underlying conditions like severe renal impairment.

Mechanism of Action

Paracip's active constituent, paracetamol (acetaminophen), exerts its primary action within the central nervous system (CNS), demonstrating high permeability across the blood-brain barrier.

Its mechanism involves the inhibition of prostaglandin synthesis, predominantly in the CNS. Paracetamol acts as a reducing co-substrate at the peroxidase site of the cyclooxygenase (COX) enzyme (specifically thought to be COX-2 in low peroxide tone environments, or a splice variant like COX-3). By reducing the ferric ion ( Fe^3+) back to the ferrous state ( Fe^2+) at the peroxidase site, it hinders the formation of the critical tyrosyl radical, which is necessary for the cyclooxygenase site to convert arachidonic acid into PGG2. This inhibition leads to a downstream reduction in the final inflammatory and pyrogenic mediator, prostaglandin E2 ( PGE2), within the CNS, particularly the hypothalamus.

Additionally, a CNS metabolite of paracetamol, AM404 ( N-(4-hydroxyphenyl)arachidonoylamide), is formed via conjugation with arachidonic acid. AM404 modulates the endocannabinoid system by activating transient receptor potential vanilloid-1 (TRPV1) receptors and inhibiting the reuptake of the endogenous cannabinoid, anandamide. This intracellular cascade contributes to the overall systemic modulation of nociception and thermoregulation.

Dosage and Administration Information

How to Use Paracip: Official Administration Guidelines

The usage of acetaminophen, the active ingredient in Paracip, is governed by structured protocols defined in regulatory documents to ensure standardized administration. These protocols specify the approved delivery routes, maximum dosage limits, and frequency intervals.


Administration Scope and Official Dosing

The medicine is officially administered via the oral route (as tablets, capsules, or liquids), as an intravenous (IV) infusion, and rectally (via suppository). Adult patients weighing 50 kg or more are typically directed to use a single dose of 650 mg or 1,000 mg. The absolute maximum total daily dose for all routes and formulations combined is 4,000 mg (4 g) in a 24-hour period.

Entity Official Administration Protocol
Frequency and Timing A minimum dosing interval of 4 hours must be observed between doses. Dosing typically occurs every 4 to 6 hours as needed.
IV Administration The required administration method is an intravenous infusion over 15 minutes.
Oral Intake May be administered with or without food.

Population-Specific and Procedural Constraints

Official instructions mandate specific adjustments for certain patient populations. For instance, the dosing interval must be extended to 6 hours for patients with severe renal impairment (CrCl leq 30 mL/min) to account for altered elimination. Additionally, a reduced maximum daily dose of 3,000 mg (3 g) or less is advised for individuals with hepatic risk factors or chronic malnutrition. Procedurally, extended-release tablets must be swallowed whole and should never be crushed or chewed, as per labeling instructions.

These instructions collectively define the full scope of proper product utilization, limiting both the quantity and frequency of use while accounting for individual physiological factors.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Paracip

Evidence for Use in Symptomatic Relief of Mild to Moderate Pain

Research explored Paracip’s role in outcomes related to physical discomfort, such as headache, muscle aches, and dental pain. The research primarily involves short-term Randomized Controlled Trials (RCTs) and meta-analyses where Paracip was evaluated in groups of generally healthy adults to assess how symptoms change over a brief time period. These studies used patient-reported outcomes describing perceived discomfort to monitor outcomes related to physical discomfort. Some trials described patterns where pain intensity scores changed during the study period, particularly within the first few hours after administration. Studies highlight changes measured during the study period when comparing observed populations. Findings help contextualize how patients reported their experience during the defined time intervals.

Evidence for Use in Fever Reduction

Paracip was observed in trials research examined changes in core body temperature in febrile participants. The research mainly consists of short-term clinical trials and systematic reviews. A significant portion of this research focused on the pediatric population, studying children experiencing conditions involving periods of heightened symptoms. Studies report how symptoms evolved in the observed populations of children and adults experiencing fever. Research highlights changes measured during the study period by tracking how quickly and to what degree core body temperature measurements changed following administration. These data show patterns related to temporary changes in body temperature.

What is Still Uncertain About Paracip Research

While many studies were observed in conditions characterized by fluctuating or episodic manifestations, a number of areas remain uncertain. Key research gaps include the lack of data to fully characterize long-term effects, as long-term effects are not fully established. Also, evidence is limited regarding the role of Paracip in specific co-existing conditions and many special populations, meaning the results apply only to the populations studied and research provides context but not individual predictions.

Key Studies & References

  1. NICE Guideline: Fever in under 5s: assessment and initial management

Frequently Asked Questions (FAQ)

Common questions about Paracip (FAQ)

Q: Is Paracip the same as the drug commonly called Acetaminophen or Paracetamol?

A: Yes, Paracip contains the active ingredient acetaminophen. This is the same medicine that is widely known internationally as paracetamol. Official documents and regulatory sources use both names to refer to this core component of the drug.

Q: What types of pain is Paracip typically used to treat?

A: Official information indicates that the active ingredient in Paracip is used for the management of mild to moderate pain. Specific types of pain often listed in regulatory documents include headaches, muscle aches, toothaches, and pain related to the common cold.

Q: Is Paracip effective for reducing fever?

A: Yes, the active ingredient in Paracip is officially classified and indicated as an antipyretic, meaning it is used for the reduction of fever. This use is consistent across regulatory documents.

Q: Does Paracip help with symptoms of the common cold or flu?

A: Regulatory information indicates the active ingredient in Paracip is a component of many combination medicines intended for the symptomatic relief of the common cold and flu. Its role is generally described as treating the associated pain and fever.

Q: What is the general classification of Paracip (e.g., analgesic, antipyretic, NSAID)?

A: Paracip's active component is classified as a non-opioid analgesic (pain reliever) and an antipyretic (fever reducer). It is officially stated that this active component is not classified as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Q: How quickly does Paracip usually start to work?

A: According to official product information, the absorption of the active ingredient after oral administration is generally described as rapid. Official documents describe the absorption of the active ingredient as rapid after oral administration.

Q: How long do the effects of a dose of Paracip typically last?

A: The minimum recommended interval between doses, as defined in official instructions, is typically 4 hours. This time frame represents the official guidance for when the medicine may be readministered.

Q: Is Paracip a medicine that helps reduce inflammation?

A: Official pharmacology descriptions indicate the active ingredient in Paracip has very weak anti-inflammatory activity. Its primary effects are described as pain relief and fever reduction.

Q: Why is Paracip often the first-choice medicine for pain and fever?

A: Global health organizations often recommend the active ingredient as a first-line therapy for pain and fever, based on its long history of use and established profile.

Q: What should a patient know about taking Paracip with other medicines that contain Paracetamol?

A: Official warnings strictly state that the active ingredient should not be used with any other product containing acetaminophen (paracetamol). This is a critical safety measure to prevent accidentally exceeding the maximum daily dose, which can lead to severe liver damage.

Q: What are the common, less serious side effects associated with Paracip?

A: Official reports of common adverse reactions often include mild gastrointestinal issues such as nausea, vomiting, and constipation. These are generally less severe than the rare, serious adverse events listed in the full safety section.

Q: What are the signs of a serious or severe side effect of Paracip?

A: Signs of a severe problem include symptoms of liver injury, such as yellowing of the eyes or skin (jaundice) or dark urine, and signs of a severe allergic reaction, such as hives, facial or throat swelling, or difficulty breathing. Regulatory information indicates that these symptoms are signs of a severe reaction.

Q: Can Paracip cause stomach upset or digestive issues?

A: Yes, regulatory documents list gastrointestinal side effects such as nausea, vomiting, abdominal pain, and constipation as possible adverse reactions. Nausea and vomiting are reported as common side effects.

Q: Is a skin rash a known side effect of Paracip?

A: Yes, rash and itching (pruritus) are listed as common side effects in official documents. Furthermore, the product labels carry warnings about the rare possibility of severe, life-threatening skin reactions.

Q: Is it common to feel drowsy or dizzy after taking Paracip?

A: Official documents indicate that dizziness and headache are listed as common side effects. The active ingredient is generally considered to have a low risk of affecting the central nervous system.

Q: What are the potential interactions between Paracip and blood-thinning medicines (e.g., Warfarin)?

A: Official drug interaction information indicates that the chronic use of high doses of Paracip's active ingredient may increase the effect of blood-thinning medicines (anticoagulants) like Warfarin. Official warnings describe the need for careful monitoring in patients taking this combination.

Q: Are there any known interactions between Paracip and common antibiotics?

A: Official drug interaction reports note that the active ingredient is known to interact with certain specific medicines, such as the antibiotic Isoniazid. Warnings exist for these specific interactions.

Q: Can Paracip be taken at the same time as Ibuprofen?

A: Regulatory descriptions note that Paracip's active ingredient is pharmacologically distinct from NSAIDs like Ibuprofen. While they are sometimes used together under certain medical protocols, official labels do not generally provide direct guidance on co-administration with other over-the-counter pain relievers.

Q: What are the general guidelines for consuming alcohol while taking Paracip?

A: Official safety warnings note that the risk of severe liver damage is increased when the active ingredient is used by a patient who regularly consumes three or more alcoholic drinks per day. This interaction is a specific point of caution in official documents.

Q: Is Paracip generally considered suitable for use during pregnancy?

A: Official guidance notes that the use of the active ingredient during pregnancy should be considered with caution. This is due to ongoing research into potential associations with neurological conditions in children, which has prompted recent label updates.

Q: Is Paracip generally considered suitable for use while breastfeeding?

A: Official reviews suggest the active ingredient is a suitable choice for nursing mothers. The amount that passes into breast milk is typically considered low, and adverse effects in infants are rare.

Q: Does taking Paracip affect the results of any common medical tests?

A: The active ingredient may interfere with certain medical tests, including some blood glucose (sugar) tests and the test for blood clotting (INR). This potential interference is a noted warning in regulatory information.

Q: Can Paracip affect a person's ability to drive or operate machinery?

A: For the oral formulation, the active ingredient does not usually affect a person's ability to drive or operate machinery. If side effects such as dizziness occur, patients should be aware of the potential impact on motor skills.

Q: Is there any research evidence on the use of Paracip for chronic pain conditions?

A: The active ingredient is officially indicated for the management of mild to moderate pain. Medical literature describes the use of the active ingredient in chronic pain management, often as part of a multi-drug regimen.

Q: Is there a risk of developing dependence or addiction with Paracip?

A: The active ingredient in Paracip is officially classified as a non-opioid analgesic. Due to this classification and its pharmacological profile, it is not considered habit-forming or associated with a risk of dependence.

Q: Why are the risks of Paracip overdose considered so serious?

A: Official warnings indicate that taking a dose higher than recommended can lead to acute liver failure. This risk is the reason the maximum daily dose is strictly limited in regulatory instructions.

Q: Is it normal to sweat after taking Paracip for fever?

A: The active ingredient works to lower a high body temperature, which often results in a decrease in fever. However, regulatory sources also note that increased sweating is a symptom that has been reported, particularly in cases of overdose.

Q: What is the advice for someone taking Paracip who also has asthma?

A: Official information indicates that the active ingredient may be administered to patients who are intolerant to salicylates and those with allergic tendencies, including bronchial asthmatics. This is based on its low risk of causing allergic reactions in this population.

Q: Can Paracip interact with medications used for seizures?

A: Drug interaction reports note interactions with certain specific anti-seizure medicines, such as Carbamazepine, which has been associated with an increased risk of liver toxicity. Warnings exist for these specific interactions.

Q: What is the official information regarding the use of Paracip for menstrual pain?

A: Regulatory documents include the active ingredient in the list of medicines used for the symptomatic treatment of period (menstrual) pains. It is often used either alone or in combination products for this indication.

Q: Does the form of the medicine (e.g., tablet, syrup) change how Paracip works?

A: While the underlying chemical action remains the same regardless of the form, official product information indicates that different routes of administration, such as an oral tablet versus an intravenous (IV) injection, can lead to different rates of absorption into the body.

Q: What research has been done on the long-term effects of using Paracip?

A: Official research reviews note that while the medicine is generally used for short-term relief at recommended doses, ongoing research continues to examine the potential long-term effects of the active ingredient, especially in specific populations.

Q: Are there any specific official warnings regarding chronic malnutrition and taking Paracip?

A: Yes, official warnings exist for patients who are experiencing chronic malnutrition or have a history of long-term alcoholism. These conditions are cited as factors that may increase the individual's risk of developing liver injury from the medicine.

Q: Are there different brand names that contain the exact same active ingredient as Paracip?

A: Yes, there are numerous different brand names and generic products that contain the exact same active ingredient, acetaminophen (paracetamol). Checking the label for the active ingredient is essential to prevent accidentally taking multiple products.

Q: Is Paracip suitable for someone with a history of stomach ulcers?

A: The active ingredient in Paracip is generally not associated with the gastrointestinal side effects (such as stomach ulcers and bleeding) that are linked to Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Q: Is the mechanism of action of Paracip fully understood by scientists?

A: Official scientific literature notes that while the antipyretic (fever-reducing) effect is well-understood, the exact mechanism for the analgesic (pain relief) effect has not been fully determined. Research continues to investigate this aspect.

Q: What are prostaglandins, and how does Paracip's action on them relate to pain?

A: Prostaglandins are natural chemicals that play a key role in causing pain and fever. Regulatory documents explain that the active ingredient works to relieve these symptoms by reducing the production or effectiveness of prostaglandins, primarily within the central nervous system.

Q: Why is it important to check cold and flu remedies for Paracip's active ingredient?

A: It is critical because many popular cold and flu remedies already contain the active ingredient. Taking multiple products with the same ingredient can quickly lead to exceeding the maximum daily dose, which carries a severe risk of liver damage.

Q: What should be done if a patient suspects they have taken too much Paracip?

A: Regulatory warnings state that if an overdose is suspected, emergency medical attention should be sought immediately, as symptoms of serious liver damage can take several days to appear.

How should Paracip be stored and disposed of?

How to Store and Dispose of Paracip?

The storage and disposal of Paracip (Acetaminophen/Paracetamol) must comply strictly with the conditions outlined in official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Requirement Condition
Temperature Store at or below 30 C (or the regional maximum limit mandated in the label).
Protection Keep the medicine in the original container/package to protect from moisture.
Child Safety Must be stored out of the sight and reach of children to prevent accidental overdose.

Disposal Instructions

Unused or expired Paracip must be disposed of in accordance with local regulatory requirements. Do not throw away medicines via wastewater or typical household waste. Instead, consult a pharmacist or local authority for information regarding pharmaceutical take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Paracip found in:

A-Z Index: